# Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

> **NCT00005849** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 15 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** bryostatin 1
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00005849
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2002-09
- **Final completion:** 2003-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005849, "Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00005849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*